Top-Rated Breast Cancer Charities for 2024
Top-Rated Breast Cancer Charities for 2024
Oct 24, 2024
October is Breast Cancer Awareness Month.
October is Breast Cancer Awareness Month.
Website
View similar charities
Ratings & Metrics
Joint Costs
Leukemia & Lymphoma Society's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 74% | $14 |
Accounting rules allow charities to report some telemarketing, direct mail, and other solicitation costs as Program expenses. CharityWatch believes that most donors do not consider a charity's solicitation activities to be the Programs they are intending to support with their donations. We therefore adjust such expenses out of a charity's reported Program expense and add it to Fundraising expense prior to calculating its rating.
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| The Leukemia & Lymphoma Society | IRS Form 990 | 13-5644916 |
| The Leukemia & Lymphoma Society | Consolidated Audited Financial Statements | Multiple |
|
Entity: The Leukemia & Lymphoma Society Document Type: IRS Form 990 Tax ID: 13-5644916 |
|
Entity: The Leukemia & Lymphoma Society Document Type: Consolidated Audited Financial Statements Tax ID: Multiple |
Governance & Transparency
CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Louis J. DeGennaro | Past President/CEO | $931,409 |
| 2 | Gwen Nichols | EVP/Chief Medical Officer | $600,712 |
| 3 | Troy Dunmire | EVP/COO | $591,651 |
|
1 Name: Louis J. DeGennaro Title: Past President/CEO Compensation: $931,409 |
|
2 Name: Gwen Nichols Title: EVP/Chief Medical Officer Compensation: $600,712 |
|
3 Name: Troy Dunmire Title: EVP/COO Compensation: $591,651 |
Analysts' Notes
CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.
CharityWatch's rating of Leukemia & Lymphoma Society includes the financial activities of the entities consolidated in The Leukemia & Lymphoma Society audited financial statements for the fiscal year ended June 30, 2023, including The Leukemia & Lymphoma Society of Canada, Inc. According to The Leukemia & Lymphoma Society (LLS) fiscal 2023 consolidated audit (Note 1(b), Principles of Consolidation): "The accompanying [audited] consolidated financial statements include the accounts of LLS and LLS's not-for-profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC), The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), and the Leukemia & Lymphoma Society research Foundation (LLSRF). Additionally, LLS is the sole member of various limited liability companies which support LLS clinical trials and research activities. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation." |
According to The Leukemia & Lymphoma Society (LLS) consolidated audit of June 30, 2023 (Note 9, Donated Services, Goods, and Media), LLS received "donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media" in fiscal 2023 on which it placed a total value of approximately $7.62 million. Of this amount, approximately $6.6 million consisted of donated media. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
According to The Leukemia & Lymphoma Society (LLS) tax filing for the fiscal year ended June 30, 2023, LLS reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III): Regarding nonfixed payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, Line 7): "LLS awards non-fixed payments such as bonuses on a discretionary basis tied to the employee performance and organiztion targets. The names of employees and the amounts that were paid found on Schedule J, Page 2, Part II, Col (B) (II)." LLS reports "Bonus & incentive compensation" payments to ten individuals in calendar year 2022, including $191,204 and $93,424 paid to Louis J. DeGennaro, President & CEO, and Troy Dunmire, EVP Chief Operating Officer, respectively. The reported total compensation in 2022 for DeGennaro and Dunmire is $931,409 and $591,651, respectively. The other eight individuals received "Bonus & incentive compensation" in 2022 that ranged from $89,255 to $54,452, with associated reported total compensation ranging from $600,712 to $423,899 (IRS Form 990, Schedule J, Part II). |